Vivos receives Nasdaq minimum bid price deficiency notice; has 180 days to cure
Vivos Therapeutics received a notice on June 5, 2026 from Nasdaq indicating noncompliance with the minimum closing bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2), based on closing bid prices from April 23 to June 4, 2026. The company has a 180-calendar-day compliance period ending December 2, 2026 to regain compliance. If the closing bid price reaches or exceeds $1.00 for 10 consecutive business days before that date, Nasdaq will issue written notification of cure. If the company does not regain compliance within the compliance period, Nasdaq may grant a second 180-day period, provided the company meets other continued listing requirements. The company also disclosed it is not in compliance with Nasdaq's $2.4 million minimum stockholders' equity requirement, but is implementing a debt-to-equity exchange with Streeterville Capital as part of its remediation plan.
Key facts
- Notice dated June 5, 2026 from Nasdaq Listing Qualifications Staff
- Noncompliance based on closing bid price from April 23, 2026 to June 4, 2026
- Requirement: minimum closing bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2)
- Compliance period: 180 calendar days from June 5, 2026, ending December 2, 2026
- Cure mechanism: closing bid price at or above $1.00 for minimum 10 consecutive business days
- Not in compliance with Nasdaq's $2.4 million minimum stockholders' equity requirement
- Company not in compliance with continued listing standards other than minimum bid price
- Second 180-day period possible if company meets other continued listing requirements and notifies Nasdaq of intent to cure
Why it matters
The deficiency notice creates a near-term listing risk for Vivos; failure to cure within the compliance periods or any extensions would result in a delisting determination and potential loss of Nasdaq trading.
Developing story
- NT 10-Q
- SCHEDULE 13D
- NT 10-K
- 8-Kthis filing
Share
Get the next chapter in your inbox — a Sentinel watches this company and briefs the next material filing the moment it lands.
Derived from 8-K filed 2026-06-08. Not investment advice. View the source filing on SEC.gov →